| ||||||||||||||||||||||||||||||
![]()
CAS号:121584-18-7
|
英文名称:Valspodar
分子式
C63H111N11O12
分子量
1215
EINECS号
1312995-182-4
MDL
MFCD00907207
Smiles
InChIKey
乙二醇化学百科
基本信息
物化性质
安全信息
生产及用途
Valspodar (PSC 833) 是一种选择性的 P-糖蛋白抑制剂,已被用作化学增敏剂用于实验性癌症的研究。 Valspodar (PSC 833) has no cytotoxicity effects at up to the concentration of 0.75 μg/mL. Valspodar (0.25, 0.5 and 0.75 μg/mL) and DOX-L are added to the DOX resistant cells, and cell kill efficacy of MDR cell type increases significantly when valspodar is administered alongside DOX-L. Valspodar (0.5 and 0.75 μg/mL), in combination with all concentrations of DOX, are most toxic and kill more than 70% of the resistant cells. Pretreatment with PSC833 decreases the IC 50 value of NSC 279836 in MDA-MB-435mdr cells to 0.4±0.02 μM in MDR cells and almost completely reverses the resistance of MDR cells to NSC 279836.
valspodar (10 mg/kg, o.p.) exhibits minimal blood-cell partitioning as reflected in its low mean blood-to-plasma ratio of approximately 0.52. Valspodar displays properties of slow clearance and a large volume of distribution. Valspodar shows properties of low hepatic extraction and wide distribution, similar to that of its structural analogue CsA. Preadministration of PSC833 to mice increases NSC 279836 fluorescent intensity in MDR tumor to 94% of that in the wild-type tumors.
上下游产品
上游产品共计:0个
下游产品共计:0个
相关产品
|
||||||||||||||||||||||||||||||
本网站展示的所有产品仅用于工业制造、技术研发、科学研究,所有产品非药品不可食用,依据国家相关法规及平台管理要求,购买相关危险物品应取得有效的资质、资格条件。 参考《应急管理部等多部门关于加强互联网销售危险化学品安全管理的通知 (应急〔2022〕119号)》 和《互联网危险物品信息发布管理规定》 Copyright © 2021-2025 chemhome123版权所有 |冀ICP备2024096099号- 1|冀公安备13042302000143号|互联网增值电信业务经营许可证:冀B2-20250121 |药品、 医疗器械互联网信息服务备案凭证备案号:(冀)-非经营性-2025-0099 |